Sugi Predict

Sugi Predict / Compounds / SCHEMBL4010135

SCHEMBL4010135

SCHEMBL4010135

CN(c1ccccc1)C1CCNCC1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SLC18A3 Q16572 1/20 0.45
▸ SIGMAR1 Q99720 1/20 0.45
▸ SLC6A2 P23975 9/20 0.45
▸ SLC6A4 P31645 9/20 0.45
▸ SLC6A3 Q01959 5/20 0.43
▸ HRH1 P35367 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ SCN1A P35498 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ SCN2A Q99250 1/20 0.43
▸ SCN3A Q9NY46 1/20 0.43
▸ GBA1 P04062 1/20 0.41
▸ HTR2C P28335 2/20 0.40
▸ NOS2 P35228 1/20 0.40
▸ IRAK4 Q9NWZ3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4389599 0.98 SLC6A2 (0.44) SLC18A3SIGMAR1SLC6A2SLC6A4SLC6A3
SCHEMBL3619850 0.89 SLC6A4 (0.48) SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL1720308 0.85 HTT (0.41) HRH1MEN1LMNAKMT2A
Hydrochloric Acid SCHEMBL23292665 0.83 HTT (0.39) HRH1MEN1LMNAKMT2A
SCHEMBL28096957 0.83 MEN1 (0.44) HRH1MEN1LMNAKMT2AGBA1
SCHEMBL4577662 0.82 SLC6A4 (0.46) SLC6A2SLC6A4SLC6A3MEN1CYP2D6
SCHEMBL11693073 0.81 ALDH1A1 (0.47) MEN1LMNAKMT2AGBA1
SCHEMBL1866454 0.81 ALDH1A1 (0.43) SLC6A2SLC6A4SLC6A3HRH1MEN1
SCHEMBL2477882 0.81 USP7 (0.36) SLC6A2SLC6A4SLC6A3HRH1MEN1
SCHEMBL2092295 0.81 NOS2 (0.44) SLC6A2SLC6A4SLC6A3NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4662217-A1 RIFABUTIN ANALOGS FOR THE TREATMENT OF BACTERIAL DISEASES BioVersys AG (CH) 2025-12-17 — — EP disclosed
EP-4452412-B1 RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE BioVersys AG (CH) 2025-10-29 — — EP disclosed
US-20250051356-A1 RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE BioVersys AG (CH) 2025-02-13 — — US disclosed
EP-4452412-A1 RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE BioVersys AG (CH) 2024-10-30 — — EP disclosed
CN-118843633-A Rifabutin analogs for treating diseases 生物验证系统股份公司 2024-10-25 — — CN disclosed
WO-2024165591-A1 RIFABUTIN ANALOGS FOR THE TREATMENT OF BACTERIAL DISEASES BioVersys AG (CH) 2024-08-15 — — WO disclosed
WO-2023118319-A1 RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE BioVersys AG (CH) 2023-06-29 — — WO disclosed
WO-2023118319-A1 RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE BioVersys AG (CH) 2023-06-29 — — WO disclosed
WO-2022073469-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN (SHANGHAI) , INC. (CN) 2022-04-14 — — WO disclosed
EP-3030241-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) 2016-06-15 — — EP disclosed
US-20070105861-A1 NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS GRUENENTHAL GMBH (DE) 2007-05-10 — — US disclosed
WO-2007019191-A2 THIAZOLOPYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-02-15 — — WO disclosed
CN-1878777-A 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis OTSUKA PHARMA CO LTD (JP) 2006-12-13 — — CN disclosed
WO-2006118749-A1 THIA-TETRAAZAACENAPHTHYLENE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-11-09 — — WO disclosed
WO-2006031929-A2 THIAZOLOPYRIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-03-23 — — WO disclosed
EP-1558567-A1 NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-08-03 — — EP disclosed
US-20040152742-A1 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-08-05 — — US disclosed
EP-1430048-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS Allergan, Inc. (US) 2004-06-23 — — EP disclosed
WO-2004039764-A1 NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-05-13 — — WO disclosed
WO-2003027102-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2003-04-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105861-A1 NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS TRPV1, TRPV5, TRPV2 SLC18A3 189/4885SIGMAR1 180/4885SLC6A2 933/4885
US-20250051356-A1 RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE RIF1, FNTB, CFTR SLC18A3 4221/4885SIGMAR1 2139/4885SLC6A2 3784/4885
US-20040152742-A1 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds MCHR2, MCHR1, NPY1R SLC18A3 1475/4885SIGMAR1 99/4885SLC6A2 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.